Neuromonics

What Neuromonics does

Neuromonics is a private medical device company (operating under SoundVida, Inc.) that delivers an FDA 510(k)-cleared (K043274) acoustic desensitization protocol for subjective tinnitus. The core product is the Neuromonics Tinnitus Treatment smartphone app, which uses proprietary "Sound Vitamins" algorithms to spectrally modify music according to each patient's audiometric profile, engaging auditory, attentional, and limbic pathways over a 26-week, two-phase protocol (Phase 1 Stabilization, Phase 2 Habituation) with monthly 1-on-1 audiologist coaching. The clinical evidence base is unusually deep for a digital health product: 14 published peer-reviewed trials across US and Australian medical centers covering 1,033+ patients, with an 83% average efficacy rate (defined as 40%+ reduction in Tinnitus Reaction Questionnaire score) and a 3.8x efficacy advantage over standard broadband masking per independent meta-analysis.

The business model is hybrid. Consumer revenue comes from a three-tier subscription: a free Phase 1 tier as a funnel, a Premium tier at approximately $199/month for the full 26-week protocol with monthly 1-on-1 coaching, and a Maintenance tier at $29.99/month for protocol graduates. Distribution runs through the iOS App Store, Google Play, and a certified provider network (audiologists and hearing care professionals trained through the free Neuromonics University program and supported by a provider portal with patient tracking and outcome reporting). All clinical services are delivered remotely via telehealth, eliminating geographic barriers within the US and reaching Australia and Indonesia. A complementary B2B technology licensing program (launched 2024) exposes the FDA-cleared algorithm to TWS/earbud manufacturers, hearing aid OEMs, occupational health providers, and wearable/sleep platforms via firmware/SoC embed, white-label companion app, or telehealth API integration. Customer segments span individual tinnitus patients (primary), audiologists and hearing care professionals (primary), veterans (Hollywood VA 96% success, Australia DVA-approved designation), musicians, employers/health plans as benefit sponsors, and hardware manufacturers as licensing counterparties.

Name

Neuromonics

Legal name

SoundVida, Inc.

Website

https://neuromonics.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Neuromonics is a private medical device company offering an FDA-cleared, app-based acoustic desensitization therapy for tinnitus patients, serving consumers via subscription, audiologists through a certified provider network, and hardware manufacturers via technology licensing.

Ownership category

akta.pro rank

Product category

Digital Tinnitus Treatment Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Offices of Physical, Occupational and Speech Therapists, and Audiologists (621340)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industries

Neurology Telemedicine Platforms (HLALAGAC), Otology & Neurotology (Ear/Hearing/Balance) (HLAKAMAC)

Keywords

• Tinnitus treatment software
• Acoustic desensitization therapy
• Digital hearing health
• Sound therapy platform
• Audiology telehealth app

Headquarters

HQ city

Westminster

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. Subscription - Premium: Premium subscription at $199/month provides full access to the 26-week, 2-phase acoustic desensitization protocol, monthly 1-on-1 coaching with a certified Neuromonics audiologist, full SMAS media library, all breathwork exercises, video coaching sessions, and progress tracking analytics. Active treatment runs 6-8 months followed by a maintenance phase.
2. Subscription - Maintenance: Maintenance tier at $29.99/month for protocol graduates. Provides Phase 2 habituation support, full SMAS media library, all breathwork exercises, and progress tracking. Does not include monthly 1-on-1 audiologist coaching, offering a lower-cost ongoing option after completing active treatment.
3. Subscription - Free (Phase 1 Stabilization): Free tier providing Phase 1 stabilization only with limited functionality: 1 album access, basic breathwork (2 exercises), and Phase 1 shielding. Does not provide full habituation or neural retraining, no full 26-week protocol, no monthly coaching, and no full SMAS media library. Serves as a funnel into Premium subscription.
4. Technology Licensing: Neuromonics licenses its FDA-cleared treatment algorithm to TWS/earbud manufacturers, hearing aid OEMs, industrial/occupational health providers, and wearable/sleep platforms. Licensing tiers include: (1) Firmware/SoC embed for native silicon integration, (2) White-label companion app delivered under partner brand in ~90 days, and (3) Telehealth API with REST and streaming endpoints for clinical platforms and EHRs. Partners receive full clinical, regulatory, and engineering support.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels9 records

Core offering

Neuromonics provides an FDA-cleared, app-based tinnitus treatment that delivers personalized spectrally-modified music (Sound Vitamins) calibrated to each patient's audiometric profile, paired with 1-on-1 audiologist coaching over a 26-week protocol. The company sells the treatment through tiered consumer subscriptions (Premium at $199/month, Maintenance at $29.99/month, Free stabilization tier) and separately licenses its treatment algorithm to hearable, hearing aid, and wearable hardware manufacturers.

Product overview

Neuromonics offers a clinically-validated, app-based tinnitus treatment platform combining two decades of peer-reviewed acoustic desensitization research. The core offering is the Neuromonics Tinnitus Treatment App, delivered via tiered subscriptions (Free, Premium at $199/month, Maintenance at $29.99/month). Premium includes the full 26-week two-phase protocol with 1-on-1 audiologist coaching. Supporting infrastructure includes the Provider Portal for clinician oversight and Neuromonics University for clinician certification. The company also operates a Technology Licensing Program enabling hardware manufacturers to embed the FDA-cleared algorithm into hearables, hearing aids, and wearable platforms via firmware integration, white-label apps, or telehealth API.

Differentiator

Problem solved

Functional benefit

Products and services

• Neuromonics Premium Subscription Full 26-week, two-phase acoustic desensitization protocol priced at $199/month, including monthly 1-on-1 audiologist coaching, full SMAS Media Library, breathwork exercises, Phase 1 and Phase 2 protocol, video coaching, and progress tracking analytics. Targeted at individual tinnitus patients seeking clinician-supervised treatment.
• Neuromonics Maintenance Subscription Post-protocol Phase 2 habituation support at $29.99/month, including full SMAS Media Library, breathwork exercises, and progress tracking, without monthly 1-on-1 clinician coaching. Targeted at protocol graduates seeking lower-cost ongoing support.
• Neuromonics Technology Licensing Program B2B technology licensing of the FDA-cleared acoustic desensitization algorithm to TWS/earbud manufacturers, hearing aid OEMs, industrial/occupational health companies, and wearable/sleep platforms, offered via three tiers: Firmware/SoC embed, white-label companion app (~90 days), and Telehealth API with REST and streaming endpoints.
• Neuromonics Tinnitus Treatment App The core smartphone application (iOS 17.0+ and Android) that delivers FDA-cleared acoustic desensitization therapy through spectrally-modified music personalized to each patient's hearing profile, with built-in coaching, progress tracking, and breathwork features. Distributed via the iOS App Store and Google Play Store.

Quantifiable outcome

• 83% average efficacy rate (40%+ reduction in TRQ score) across 14 published peer-reviewed clinical trials involving 1,033+ patients
• +8 more outcomes

Named customers5 records

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered minor and core.

• Advanced Hearing Care Center (Boston, MA)minorStrategic or Co-development PartnerAudiology practice of Dr. Sarah Johnson, Senior Audiologist and Tinnitus Treatment Specialist. Dr. Johnson is featured as a Neuromonics provider and clinical champion, treating tinnitus patients with the Neuromonics protocol and providing testimonial endorsement.
• Dr. Beth AlbertominorStrategic or Co-development PartnerAudiologist with 25+ years of clinical experience using Neuromonics. Developed tinnitus during chemotherapy. One of the first audiologists in the US to work with Neuromonics (2000). Provides extensive clinical testimonial and case study data from patient outcomes.
• Hollywood Veterans Affairs Medical CentercoreStrategic or Co-development PartnerIndependent clinical study conducted at Hollywood VA Medical Center achieving 96% success rate among veteran patients (35 subjects). Presented at Annual VA/DOD Joint Audiology Conference. Independent investigator-led study validating the Neuromonics protocol for veteran populations.
• TWS/Earbud Manufacturers (Potential Licensing Partners)minorOEM/ Whitelabel/ Licensing PartnerTarget licensing partners for embedding the Neuromonics FDA-cleared clinical algorithm into true wireless stereo earbuds and consumer audio devices. Enables differentiation from commodity audio with an FDA-cleared clinical mode and recurring revenue through prescription and care-pathway distribution.
• Hearing Aid OEMs (Potential Licensing Partners)minorOEM/ Whitelabel/ Licensing PartnerTarget licensing partners for hearing aid manufacturers. Embedding Neuromonics' validated tinnitus treatment into existing audiology channels without a separate device. Audiologists already trust the brand — the platform provides a treatment, not just a feature.
• Industrial/Occupational Health Companies (Potential Licensing Partners)minorOEM/ Whitelabel/ Licensing PartnerTarget licensing partners for occupational health providers serving workforces with high noise exposure (military, aviation, manufacturing, music production). Embed prevention and treatment into hearing protection already issued to workers.
• Wearable/Sleep Platforms (Potential Licensing Partners)minorOEM/ Whitelabel/ Licensing PartnerTarget licensing partners for sleep and wellness wearable platforms. Tinnitus disrupts sleep onset for tens of millions of users. Licensing the Neuromonics protocol addresses the underlying neurology rather than masking symptoms in the moment. Positions for category of subscription, prescription, and reimbursement revenue.
• Australia Department of Veterans' Affairs (DVA)coreStrategic or Co-development PartnerNeuromonics is designated as an approved tinnitus treatment by Australia's DVA for veterans, alongside hearing aids and CBT. This regulatory designation validates the treatment for one of the largest veteran populations globally and provides a reimbursement pathway.
• Dr. Lynnette B. Bardolf, PhD, CCC-AcoreStrategic or Co-development PartnerChief Audiologist at Neuromonics. 25-year US Army veteran and former Compensation and Pension Audiologist for the Department of Veterans Affairs. Evaluated, diagnosed, and documented hearing damage of service members and veterans throughout her clinical career. Brings veteran-specific clinical perspective to product development and clinical protocols.

Scale indicators16 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Neuromod Devices: Maker of Lenire, a bimodal neuromodulation tinnitus treatment device combining tongue-tip stimulation and audio. Neuromonics' most direct competitor in FDA-cleared, clinically validated tinnitus treatment; Neuromonics explicitly positions its $199/mo app against Lenire's ~$4,000+ upfront hardware cost.

Broad incumbents

• Signia (WS Audiology): Major hearing-aid manufacturer offering built-in tinnitus therapy programs (e.g., Signia Notch Therapy) integrated into its devices. Comparable as a reimbursement channel and potential licensing acquirer of Neuromonics' algorithm for embedded tinnitus care.
• Widex: Hearing-aid manufacturer with the proprietary 'Widex Zen' tinnitus management program combining fractal tones with amplification. Directly overlaps Neuromonics' audiologist distribution channel and provides a device-integrated tinnitus alternative.
• Oticon (Demant): Demant-owned hearing-aid brand distributing Tinnitus SoundSupport across its product line via audiologists. Competes for the same audiology referral channel that Neuromonics is targeting through Neuromonics University.
• Phonak (Sonova): Sonova's flagship hearing-aid brand offering the 'Phonak Tinnitus Balance Portfolio' with broadband and nature sounds. Largest commercial hearing-aid channel globally, making it the most consequential potential licensing partner or competitive threat.
• Starkey: US hearing-aid manufacturer with tinnitus support built into its devices and audiologist training programs. Strong US market overlap with Neuromonics' domestic clinician network and benefit-sponsor channels.
• GN Hearing (ReSound): ReSound and Beltone parent with built-in tinnitus sound generator and smart-app integration. Competes on integrated device-plus-app tinnitus management versus Neuromonics' standalone treatment app.
• Cochlear: Global cochlear-implant leader with a growing hearing-care portfolio, including acoustic and electrical tinnitus management programs. Represents both a complementary distribution channel and a potential acquirer of clinical tinnitus IP.

Emerging players

• Oto: Digital tinnitus therapy app combining CBT-based coaching and sound therapy delivered via smartphone. Targets the same patient segment as Neuromonics' DTC subscription but with a different therapeutic modality (CBT-led rather than acoustic desensitization).
• SoundCure: Developer of patented S-Tones tinnitus treatment technology with clinical research and audiologist channel presence. Comparable as a niche, evidence-driven tinnitus therapy competing for the same provider-referral economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights5 records

Customer concentration

• Xx.com/Neuromonics
• Facebookfacebook.com/neuromonicstinnitustreatment
• LinkedInlinkedin.com/company/84501

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuromonics